Revised SPC: Episenta (sodium valproate) solution for injection and prolonged release granules – all strengths

SPC updated to include interaction with metamizole, an inducer of CYP2B6 and CYP3A4, which may cause a reduction in plasma concentrations of valproate with potential decrease in clinical efficacy. Clinical response and/or drug levels should be monitored as appropriate.

Source:

electronic Medicines compendium